Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PDGFRB
REST API REST API
Homo sapiens
PDGFRB is differentially expressed in 232 experiments: 163 organism parts: bone marrow, thymus, ... (161 more);, 190 disease states: normal, glioblastoma, ... (188 more);, 75 cell types 295 cell lines 20 compound treatments and 64 other conditions.
Synonyms CD140b, PDGFR, PDGFR1, JTK12
Orthologs Pdgfrb (Mus musculus)   pdgfrb2 (Danio rerio)   F1N868_CHICK (Gallus gallus)   F1MBP1_BOVIN (Bos taurus)   Pdgfrb (Rattus norvegicus)   Pvr (Drosophila melanogaster)   PDGFRB (Xenopus laevis)   PGFRB_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, phosphorylation, protein binding, cytoplasm, positive regulation of cell proliferation, membrane, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, receptor binding, positive regulation of MAP kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, signal transducer activity, hemopoiesis, ATP binding, integral to plasma membrane, nucleus, receptor activity, nucleotide binding, kinase activity, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, apical plasma membrane, integral to membrane, tissue homeostasis, regulation of actin cytoskeleton organization, nitrogen compound metabolic process, signal transduction, protein kinase activity, cell chemotaxis, positive regulation of smooth muscle cell migration, in utero embryonic development, regulation of peptidyl-tyrosine phosphorylation, platelet-derived growth factor beta-receptor activity, kidney development, positive regulation of ERK1 and ERK2 cascade, adrenal gland development, platelet-derived growth factor receptor signaling pathway, positive regulation of cell migration, cardiac myofibril assembly, platelet activating factor receptor activity, positive regulation of chemotaxis, smooth muscle tissue development, growth factor binding, platelet-derived growth factor binding, skeletal system morphogenesis, positive regulation of smooth muscle cell proliferation, platelet-derived growth factor receptor binding, positive regulation of mitosis, protein autophosphorylation, protein phosphorylation, retina vasculature development in camera-type eye, positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway, metanephric glomerular mesangial cell proliferation involved in metanephros development, platelet-derived growth factor receptor-beta signaling pathway, positive regulation of reactive oxygen species metabolic process, metanephric glomerular capillary formation, positive regulation of calcium ion import, positive regulation of phosphatidylinositol 3-kinase cascade, positive regulation of DNA biosynthetic process, aorta morphogenesis, smooth muscle cell chemotaxis, vascular endothelial growth factor-activated receptor activity, platelet-derived growth factor-activated receptor activity
InterPro Term Ig_sub, Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ig_I-set, Tyr_kinase_VEGFR_rcpt_N, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_CSF1/PDGF_rcpt, Se/Thr_kinase-like_dom
Gene-Disease Assocation MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA
UniProt Accession Q59F04, P09619, E5RJ14, E5RII0, E5RH16
Search EB-eye ENSG00000113721
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-18005, E-GEOD-2450, E-GEOD-4717, E-MTAB-62, ... (31 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
BT474
2
E-MEXP-440, E-MTAB-62
WI38
2
E-MTAB-37, E-MTAB-62
BC-2
1
E-GEOD-2149
pc3
1
E-MTAB-62
SH4
1
E-MTAB-37
289 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, ... (37 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
BDCA4+ dentritic cells
1
E-AFMX-5
tumor cell
1
E-MEXP-1327
CD71+ early erythroid
1
E-AFMX-5
epidermal keratinocyte
1
E-GEOD-2822
plasma cell
1
E-MEXP-2360
69 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (55 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-4412
prostate carcinoma
1
3
E-MTAB-62, E-GEOD-96, E-MEXP-2034, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
bladder carcinoma
2
E-TABM-147, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
184 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-15205, E-GEOD-5741, E-GEOD-5824, ... (13 experiments)

Factor Value U/D Experiments
TTA
1
E-MEXP-2590
actinomycin D
1
E-GEOD-6400
unknown
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
Cxcl12
1
E-GEOD-7307
LDL
1
E-GEOD-5741
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-4271, E-GEOD-19743, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-20847, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-GEOD-2292, E-TABM-321, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-666, E-GEOD-19519, ... (22 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-6802

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-22541

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.236 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM